(Reuters) – Omeros Corp said on Monday it will discontinue a trial studying its therapy to treat a type of kidney disease after it failed to meet the main goal of the late-stage study.
An interim analysis showed the drug failed to demonstrate a statistically significant improvement in reducing elevated levels of protein in urine compared to placebo.
The company was studying narsoplimab for the treatment of immunoglobulin A (IgA) nephropathy, in which germ-fighting protein builds up in the kidneys.
Shares of the company were halted for trading before the bell.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shinjini Ganguli)
